ASIAPEDIA

Multimedia

Pharmaceuticals in EVFTA: How Foreign Investors Can Qualify For the Preferential Tariffs

Return to search

Infographics

Pharmaceuticals in EVFTA: How Foreign Investors Can Qualify For the Preferential Tariffs

Download
Posted On September 2020
Presenter(s)
Do Thanh Huyen
Do Thanh Huyen
Manager, Business Intelligence
emaillinkedin

Foreign investors have continued to target Vietnam’s pharmaceuticals industry due to low production costs and a large domestic market where demands are still not met. To encourage investment, the Vietnamese Government amended the Law on Pharmacy, waiving the requirements for clinical trials of new drugs, except for vaccines. Combined with the enforcement of the EVFTA, which has eliminated about 71 percent of import tariffs once applied to pharmaceutical products in Vietnam, it is an opportune time to make an investment in the pharmaceutical industry here. 

To help investors uncover their advantages, capture opportunities, mitigate challenges, and better understand the steps to access the Vietnamese market through the EVFTA, Dezan Shira & Associates held the second episode of our EVFTA series, shedding light on the pharmaceutical industry.

The webinar, conducted by Do Thanh Huyen, Business Intelligence Assistant Manager, on September 3, 2020 provides insights on:

  • An overview of Vietnam's pharmaceutical industry
  • Emerging opportunities and remaining barriers in Vietnam's pharmaceutical industry under the EVFTA 
  • Market entry strategies  

For a copy of the presentation, please click the download button.

We hope you find the webinar helpful. Should you have any further concerns or questions when applying the solutions brought up in the webinar, please do not hesitate to contact us.

Get in touch

We provide expert advisory and corporate services across Asia, guiding businesses through complex markets and regulations.

Have Any Questions?

Reach out to our local experts, we’ll respond within one business day.

captcha image

It appears that you have recently submitted an inquiry on this topic. Would you like to
replace your previous submission with this one?